Pepticom is participating in the BioDigital conference this week.
If you are interested to learn more on Pepticom’s AI peptide design & discovery technology, please contact Shoshi.Keynan@pepticom.com
Jun 2020
If you are interested to learn more on Pepticom’s AI peptide design & discovery technology, please contact Shoshi.Keynan@pepticom.com
to identify novel inhibitors that can fight the COVID19. We are looking for partners to validate and develop these peptide drug candidates. For more information:
https://www.israel21c.org/30-israeli-medical-tech-solutions-to-help-fight-coronavirus/ For more information : Shoshi.Keynan@pepticom.com
Meet us and learn how Pepticom’s AI peptide design platform can augment your drug discovery process. For more information: shoshi.keynan@pepticom.com
https://www.biopharmatrend.com/m/map/
Pepticom’s CTO, Dr. Amit Michaeli, will present at the Artificial Intelligence and Machine Learning for Advanced Drug Discovery and Development Conference in London, May 28-29.
Pepticom is pleased to welcome Dr. Waleed Danho to its Scientific Advisory Board. Dr. Waleed Danho held the position of Distinguished Research Leader at Hoffmann-La
Pepticom is delighted to present our latest article, published in the Journal of Immunology, on the subject of Computationally Designed Bispecific MD2/CD14 Binding Peptides Show
Dr. Lerner will discuss Pepticom’s exciting design work on TLR4 activators in “the Cyclic Peptide Design Challenges” session.
The talk will take place on September 24 at 13:25.
Dr. Riviere has over 25 years of biopharmaceutical industry experience with R&D leadership roles in target and drug discovery, nonclinical and early-stage clinical development. He
For more information: maayan.elias@pepticom.com.
We will be happy to see you there! For more information, please contact: maayan.elias@pepticom.com.
For more information, please contact: maayan.elias@pepticom.com
Dr. Amit Michaeli, Pepticom CTO, will discuss principles from our algorithm: From Finance to AI Drug Discovery. For more information: amit.michaeli@pepticom.com.
The conference will take place on September 13-14, 2018. We will be happy to meet during the conference. For more information: immanuel.lerner@pepticom.com.
The risk and return heuristic describes a novel new approach for Peptide discovery. ( https://www.researchtrends.net/tia/title_issue.aspid=26&in=0&vn=18&type=3″
The conference will take place on March 12-14 in Amsterdam, The Netherlands. For more information:maayan.elias@pepticom.com.
If you have a protein target and want to find a cyclotide that binds it, please contact: amit.michaeli@pepticom.com.
For more information: maayan.elias@pepticom.com.
The talk: Artificial intelligence designed TLR4 peptide activators, will take place on September 12
For winning the prestigious 2017 Kaye Innovation Award for dramatic improvements in drug discovery methods.
For more information and schedule: andre.miodezky@pepticom.com.
For more information: maayan.elias@pepticom.com.
Bringing our unique technology together with American minds to create leading products in the 21st century. Come and meet us: amit.michaeli@pepticom.com.
Come and meet us on June 1-2. For more information, please contact: maayan.elias@pepticom.com.
Meet us at the Israeli BioMed 2017 on May 25 at booth 8 in the startup pavilion area. For more info, contact: maayan.elias@pepticom.com.